Terns is developing a portfolio of small molecule product candidates in the oncology and obesity space. The pipeline contains three clinical-stage development programs, including an allosteric BCR-ABL ...
Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability data that fell short of expectations as well as evidence the ...
Good day, and thank you for standing by. Welcome to the Terns Pharmaceuticals TERN-701 December 2025 Data Update Conference Call. Please be advised that today's conference is being recorded. I would ...
Terns Pharmaceuticals’ prediction that its shelved metabolic dysfunction-associated steatohepatitis (MASH) drug TERN-501 could be effective against obesity in a combination treatment appears to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results